Source:http://linkedlifedata.com/resource/pubmed/id/12665842
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2003-3-31
|
| pubmed:abstractText |
This study was designed to evaluate the results of high-dose therapy followed by purged autologous stem cell transplantation (ASCT) for patients with low-grade follicular non Hodgkin's lymphoma (LGFL), and the prognostic significance of PCR detection of residual Bcl-2/IgH-positive cells after ASCT. Between 1992 and 1998, 49 patients with LGFL received total body irradiation and high-dose cyclophosphamide followed by purged ASCT. PCR amplification of the Bcl-2/IgH rearrangement was performed at diagnosis, on stem cell collections before and after purging and on bone marrow and blood samples after ASCT. With a median follow-up of 76 months (37-103) 34 patients remain alive and event-free. A total of 20 patients had disease recurrence, three patients developed secondary myelodysplastic syndrome (MDS). In all, 11 patients died; 10 deaths were because of recurrent disease, one because of MDS. Kaplan-Meier estimates of event-free survival (EFS) and overall survival (OS) at 5 years were 65% (+/-7%) and 77% (+/-6%), respectively. Patients who achieved a sustained molecular complete response (CR) had a lower risk of disease recurrence and experienced significantly longer EFS (93% (+/-6%) vs 11% (+/-7%) P=0.0008) and OS (100 vs 55% (+/-12%) P=0.0057). In conclusion, myeloablative therapy followed by purged ASCT may induce long EFS in patients with LGFL. The achievement of sustained molecular CR after ASCT improves EFS and OS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
467-73
|
| pubmed:dateRevised |
2005-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:12665842-Adult,
pubmed-meshheading:12665842-Aged,
pubmed-meshheading:12665842-Antineoplastic Agents,
pubmed-meshheading:12665842-Combined Modality Therapy,
pubmed-meshheading:12665842-Disease-Free Survival,
pubmed-meshheading:12665842-Female,
pubmed-meshheading:12665842-Flow Cytometry,
pubmed-meshheading:12665842-Gene Rearrangement,
pubmed-meshheading:12665842-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12665842-Humans,
pubmed-meshheading:12665842-Immunoglobulin Heavy Chains,
pubmed-meshheading:12665842-Lymphoma, Follicular,
pubmed-meshheading:12665842-Male,
pubmed-meshheading:12665842-Middle Aged,
pubmed-meshheading:12665842-Polymerase Chain Reaction,
pubmed-meshheading:12665842-Prognosis,
pubmed-meshheading:12665842-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:12665842-Survival Rate,
pubmed-meshheading:12665842-Transplantation, Autologous,
pubmed-meshheading:12665842-Whole-Body Irradiation
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Service d'Hématologie, Centre Hospitalier Universitaire Nantes, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|